EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data
US Filing Was Submitted In September
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.